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In a recent paper published in
Development, Koide et al. provide
evidence for a negative regulatory
action of 7-dehydrocholesterol reductase
(DCHR7) on the Hedgehog pathway
(Koide et al., 2006). In a series of
elegant experiments, the authors show
that: (1) DHCR7 expression is intimately
linked to the expression of Sonic
Hedgehog (Shh); (2) DHCR7 functions
as a negative regulator of Shh signalling
in various model systems; (3) the
reductase activity of DHCR7 is
indispensable for DCHR7’s inhibitory
action, whereas the N terminus seems to
be essential in this respect; and (4)
DHCR7 acts at the level of Smoothened
(Smo).
These findings surprised us at first, as
we recently published that mouse patched
1 (Ptch1) secretes vitamin D3, which
subsequently binds to and inhibits Smo
(Bijlsma et al., 2006). A consequence of
our findings is that a defect in (or the
absence of) DHCR7 that leads to the
accumulation of its substrate, 7-
dehydrocholesterol (7-DHC, the precursor
of vitamin D3), should inhibit Smo
activity (through enhanced Ptch1-
dependent vitamin D3 secretion). Indeed,
we have shown that the DHCR7 inhibitor
AY-9944 or the genetic absence of
DHRC7 [using Dhcr7–/– cells (Cooper et
al., 2003)] results in the increased
repression of Smo. By contrast, however,
the experiments performed by Koide et al.
indicate that knocking down or
pharmacologically inhibiting DHCR7 has
a stimulatory effect on the Hedgehog
pathway rather than an inhibitory one,
indicating that DHCR7 acts as a negative
regulator of the Hedgehog pathway. Thus,
these data apparently conflict with our
work, and also with earlier papers that
suggest a positive regulatory role for
DHCR7 on the Hedgehog pathway.
Obviously these paradoxical results raise
questions.
Upon further critical evaluation of the
paper of Koide et al., we could appreciate
several subtle differences in experimental
set-up that explain most of the apparent
discrepancies. For instance, most of the
experiments Koide et al. presented were
performed in the presence of exogenous
Shh. As a result, the effect of Ptch1 on
Smo activity was not taken into account
and the inhibitory role of vitamin D3
(inhibiting Smo after translocation across
the cell membrane) was thus overlooked.
In such a model system, changing the
levels of intracellular 7-DHC and,
consequently, of vitamin D3 by
modulating DHCR7 levels does not
increase the extracellular vitamin D3
concentration and cannot mediate Smo
inhibition. It would be interesting to see
the effect of DHCR7 knock down on
Hedgehog pathway reporter activity in the
absence of Shh. 
Another complicating factor in the
interpretation of the effects of DHCR7
knock down on Hedgehog pathway
activity is the ectopic expression of Shh
the authors described after DHCR7
morpholino injection [see figures 5 and
6 in Koide et al. (Koide et al., 2006)].
As Shh is not a known target gene
of the Hedgehog pathway, this
upregulation is puzzling and provides
another source of Shh to paralyze Ptch1
in its action as described above. In this
regard, it is important to note that in
our own experimental set-up, we have
aimed to eliminate the contribution of
Shh to be able to focus on the action of
Ptch1, and once more the differences
between models systems in studying
Hedgehog signal transduction become
apparent.
Although (or maybe because) Koide et
al. circumvented Ptch1 inhibitory activity
in their model system, it was elegantly
shown that the reductase activity of
DHCR7 is not necessary for the inhibitory
action on the Hedgehog pathway. Using
various DHCR7 mutant constructs, Koide
et al. show that the inhibitory activity of
DHCR7 is mediated via the N-terminal
domain of DHCR7 (Koide et al., 2006).
These results should, however, be
interpreted with care, as one should
realize that the deletion of a large N-
terminal part of a protein might remove
essential signal- and start-transfer
sequences, thereby perturbing the
orientation of the protein in the
membrane. 
Combining the data of Koide et al. with
our own suggests that DHCR7 plays a
dual role in Hedgehog signalling.
Through its enzymatic activity, it limits
vitamin D3 levels in the cell, thereby
reducing vitamin D3 secretion via Ptch1
and, subsequently, Ptch1-dependent Smo
inhibition. Alternatively, via a currently
unknown mechanism but independently
of its enzymatic activity, DHCR7
functions as a negative regulator of
Shh signalling. The net effect and
physiological relevance of these opposing
activities of DHCR7 seems a challenging
dilemma that needs to be resolved in the
near future. Also, as the authors point out
themselves, the duality of DHCR7 action
on Hedgehog pathway activity is reflected
in the different, often incomprehensible,
phenotypes of Smith-Lemli-Opitz
syndrome (SLOS) patients. 
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Phenotypes of DHCR7-defective
embryos
As noted by Bijlsma et al., impaired
function of DHCR7 might be expected to
lead to accumulation of this enzyme’s
substrate, 7-DHC (7-dehydrocholesterol).
According to their hypothesis, a build up of
7-DHC would subsequently be converted to
vitamin D3, which their new data suggest
functions as a direct Smo antagonist. Thus,
DHCR7 should function as a positive
regulator of Hh signaling, which is
consistent with the common opinion held in
the field. However, current embryological
phenotypes of loss of DHCR7 in both mice
and Xenopus are not consistent with this
simple view. Although DHCR7-deficient
mutant mice (deficient in reductase activity
due to the elimination of specific exons)
display cholesterol deficiency (showing
both accumulation of 7-DHC and low
cholesterol), they fail to show any obvious
defects consistent with a loss of Hh
signaling (Fitzky et al., 2001; Waage-
Baudet et al., 2003; Wassif et al., 2001; Yu
et al., 2004). Furthermore, we have found
that the overexpression of DHCR7 inhibits
Hh signaling in Xenopus embryological
assays and, consistent with this observation,
that the knockdown of DHCR7 by DHCR7
morpholino injection promotes Hh
signaling. These findings together imply
that the function of DHCR7 in Hh signaling
is complex and that DHCR7 has other roles
in addition to its previously anticipated role
in cholesterol biosynthesis. 
Reductase activity of DHCR7 in
early frog development
Our analyses using DHCR7 Xenopus
mutants defective in reductase activity, as
well as our use of a pharmacological
inhibitor of the reductase, suggest that
DHCR7’s negative effects on Hh signaling
are independent of its enzymatic activity.
Whether this reductase-independent
inhibitory effect is observed only during
early Xenopus embryogenesis, or whether it
occurs at later stages of development
requires further investigation. In this regard,
it would be important to find out when de
novo cholesterol biosynthesis occurs during
Xenopus embryogenesis. Tint et al. (Tint et
Smith-Lemli-Opitz syndrome (SLOS) is
caused by defects in 7-dehydrocholesterol
reductase (DHCR7), a key enzyme in the
final step of cholesterol biosynthesis.
Cholesterol has been suggested to play
roles in Hedgehog (Hh) signaling by either
the direct cholesterification of Hh ligands or
by regulating the function of Smoothened
(Smo), a hedgehog pathway inducer. Many
developmental malformations attributed to
SLOS occur in tissues and organs in which
Hh signaling is required for development.
However, the precise role of DHCR7
deficiency in this disease remains
confusing. Our recent findings (Koide et al.,
2006) in Xenopus, and a recent report by
Bijlsma et al. (Bijlsma et al., 2006),
underscore the complexity of DHCR7
function in Hh signaling and the condition
of SLOS. 
Before we consider the implications of
these findings further, we would like to
address certain statements in the Bijlsma
et al. Correspondence regarding the role of
DHCR7 in Xenopus. We examined the role
of DHCR7 in Hh signaling in several
tissues during early Xenopus
embryogenesis. We found that DHCR7
appears to function in an inhibitory
fashion, paradoxical to the mainstream
view of its role in Hh signaling. Further
investigation will be necessary to
determine how broadly DHCR7 functions
in this way. In addition, our paper
concludes that the reductase activity
of DHCR7 is ‘dispensable’ for its
inhibitory action, not ‘indispensable’ as
stated by Bijlsma et al. in their
Correspondence. Our model also suggests
that DHCR7 may act in the receiving cells
either at the level, or downstream, of Smo,
and seemingly upstream of Gli. Lastly,
because our manuscript was published
before the Bijlsma et al. paper (Bijlsma et
al., 2006), we were unaware of the
possible effects of vitamin D3 on Smo.
However, in light of this new and
important observation, it is useful to
examine the experimental approaches,
results and conclusions of these papers to
determine whether one model can take
into account the findings of these two new
studies. 
al., 2006) recently reported that most of the
cholesterol accumulated in early mouse
embryos is maternal in origin, and that
endogenous cholesterol synthesis in
embryos rapidly increases after E10-E11 in
the brain, and E12-E14 in the liver and lung.
A similar scenario can be imagined for the
early frog embryo, as much of the material
required for early embryogenesis is packed
into the egg maternally during oogenesis.
Hence, we can imagine a situation in which
the reductase activity of DHCR7 is
dispensable for early embryos, and thus the
loss of DHCR7 may not lead to an
accumulation of 7-DHC or vitamin D3 to
inhibit Smo during early development. 
Vitamin D3 and 7-DHC
It seems quite reasonable to extrapolate the
model of Bijlsma et al. that mouse Ptch1
acts in the secretion of vitamin D3, and that
this is the general mechanism by which
Patched negatively regulates Smo activity.
Bijlsma et al.’s treatment of zebrafish
embryos with vitamin D3 (Bijlsma et al.,
2006) is consistent with their model, giving
rise to Smo loss-of-function phenotypes.
However, the effects of 7-DHC and the role
of DHCR7 on this vitamin D3 effect in
developing zebrafish embryos was not
studied. Additionally, the exogenously
applied concentrations of vitamin D3 appear
to be quite high, and therefore the
physiological relevance of these
experiments is difficult to assess at present.
Finally, as noted by Bijlsma et al., vitamin
D3 production from 7-DHC requires
exposure to UV light. It is of interest to note
that Xenopus and zebrafish embryos
develop perfectly normally in the dark (in
the complete absence of UV light). Hence,
either vitamin D3 cannot be photoconverted
from 7-DHC and thus this process is
unlikely to play a major role in affecting Hh
signaling during early embryogenesis, or
vitamin D3 may be maternally accumulated
in early Xenopus and zebrafish embryos.
This is another important question to
examine in the future.
Isoforms of DHCR7
Recently, three isoforms of DHCR7 have
been isolated in Xenopus, and splice variants
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of DHCR7 in rats and mice have also
been identified (Tadjuidje and Hollemann,
2006; Lee et al., 2002). Interestingly,
the Xenopus isoforms do not display
identical phenotypes when assayed by
overexpression (Tadjuidje and Hollemann,
2006), raising the possibility that different
forms of DHCR7 may display different
activities. In light of the apparent dual
function of DHCR7, it is tempting to
speculate that different forms of DHCR7 are
expressed in different tissues, and that these
display different levels of reductase and Hh
antagonistic activities. The difference
between our results in Xenopus embryos
and Bijilsam et al.’s in cell culture could be
partly explained by the differential
expression of different DHCR7 isoforms
that possess different activities. 
Future studies
In light of these new findings on the role of
Ptch1 on Smo via vitamin D3, our future
work should include an examination of the
role of vitamin D3 during Xenopus
embryogenesis, and whether the
manipulation of DHCR7 expression
influences the availability of vitamin D3 to
regulate Hh signaling. Additionally, it
would be useful to examine Gli-reporter
gene activity in the DHCR7 morpholino-
injected embryos in the absence of Shh
signaling, as our assay was always done in
the presence of exogenous or endogenous
Shh signaling. Lastly, using various DHCR7
deletion and point mutations, we found that
the inhibitory role of DHCR7 can be
uncoupled from the reductase enzymatic
activity. While the result is supportive of the
notion that the inhibitory activity is
reductase independent and mediated via the
N-terminal of DHCR7, it is not conclusive
because tampering with the structure of any
protein could result in a change in protein
activities for various reasons. Therefore,
further mutational analyses of DHCR7,
together with structural studies, should be
performed to better define the role of
DHCR7. 
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